Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Mar 20, 2025
Trial Information
Current as of April 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of three different substances—LSD, psilocybin, and DMT—on healthy people. The researchers want to find out if these substances produce similar experiences when given in controlled doses. To make sure that the timing of the effects is comparable, they will use another drug called ketanserin during the study. Participants will receive these substances in a safe environment, and the trial is currently looking for volunteers.
To be eligible for this study, participants should be fluent in German and understand the study's procedures and risks. They should be willing to follow the rules, including not using any illicit drugs during the trial and avoiding heavy machinery for 48 hours after taking the substances. Additionally, participants must have a body mass index (BMI) between 17 and 34.9. It's important to note that people with certain medical conditions, a history of serious mental health issues, or those who smoke heavily or drink excessively may not be able to participate. If you join, you can expect a close examination of how these substances might affect your state of consciousness, all while being monitored by professionals.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Good understanding of the German language
- • 2. Understanding of procedures and risks associated with the study
- • 3. Willing to adhere to the protocol and signing of the consent form
- • 4. Willing to refrain from the consumption of illicit psychoactive substances during the study
- • 5. Willing not to operate heavy machinery within 48 h after administration of a study substance
- • 6. Willing to use effective birth control throughout study participation
- • 7. Body mass index 17 - 34.9 kg/m2
- Exclusion Criteria:
- • 1. Relevant chronic or acute medical condition
- • 2. Current or previous major psychiatric disorder (e.g. psychotic disorder)
- • 3. Psychotic disorder or bipolar disorder in first-degree relatives
- • 4. Hypertension (SBP\>140/90 mmHg) or hypotension (SBP\<85 mmHg)
- • 5. Bradycardia (\< 45 bpm)
- • 6. Prolonged QTc interval (males: \>450 ms, females: \>470 ms)
- • 7. AV block II° (Mobitz type and Webckebach type) and III°
- • 8. Hallucinogenic substance use (not including cannabis) more than 20 times or any time within the previous two months
- • 9. Pregnancy or current breastfeeding
- • 10. Participation in another clinical trial (currently or within the last 30 days)
- • 11. Use of medication that may interfere with the effects of the study medication
- • 12. Tobacco smoking (\>10 cigarettes/day)
- • 13. Excessive consumption of alcoholic beverages (\>15 drinks/week)
Trial Officials
Matthias E Liechti, Prof. Dr. MD
Principal Investigator
University Hospital, Basel, Switzerland
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, , Switzerland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported